VRT106 with Camrelizumab and Apatinib for Advanced Liver Cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of three drugs—VRT106 (a new oncolytic virus therapy), camrelizumab (an immune-boosting drug), and apatinib (a targeted cancer drug)—to treat advanced hepatocellular carcinoma (HCC), a type of liver cancer. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 75 years old
- Confirmed advanced liver cancer (HCC) diagnosis by biopsy or imaging
- Good overall health status (able to do light activity)
- Expected to live at least 3 more months
- No severe problems with blood counts, liver, kidneys, blood clotting, or heart function
- Never received camrelizumab, apatinib, oncolytic virus therapy, or gene therapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial tests whether combining two drugs, camrelizumab (an immunotherapy) and apatinib (a targeted therapy), can prevent liver cancer from coming back in people who've had surgery or ablation to remove their tumor. It's for patients with a high risk of recurrence.
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
This trial tests a combination of radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy drug (apatinib) to shrink liver cancer that cannot be removed with surgery. The goal is to make the cancer small enough for surgery later.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.